Lineage Cell Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $249.13M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | During market hours | $1.10M | $-0.03 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | During market hours | $1.70M | $-0.03 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 5, 2026 | During market hours | $6.60M | $0.00 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | During market hours | $3.70M | $-0.13 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | During market hours | $2.80M | $-0.13 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | During market hours | $1.50M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 10, 2025 | During market hours | $2.90M | $-0.02 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | During market hours | $3.80M | $-0.02 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 7, 2024 | During market hours | – | – | – |
Press releases
Announcements Lineage Cell Therapeutics filed with the SEC
LINEAGE CELL THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Results of operations · EX-99.1 to Form 8-K
LINEAGE CELL THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Results of operations · EX-99.1 to Form 8-K
LINEAGE CELL THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Results of operations · EX-99.1 to Form 8-K
LINEAGE CELL THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Results of operations · EX-99.1 to Form 8-K
LINEAGE CELL THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Results of operations · EX-99.1 to Form 8-K
OPREGEN ® (RG6501) 36-MONTH VISUAL ACUITY RESULTS FEATURED AT CLINICAL TRIALS AT THE SUMMIT 2025
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
LINEAGE CELL THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Results of operations · EX-99.1 to Form 8-K
LINEAGE CELL THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Results of operations · EX-99.1 to Form 8-K
Lineage Cell Therapeutics Announces CLOSING OF SECOND TRANCHE OF PREVIOUSLY ANNOUNCED Registered Direct Offering
Shareholder vote results · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
LINEAGE CELL THERAPEUTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Results of operations · EX-99.1 to Form 8-K
LINEAGE CELL THERAPEUTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Results of operations · EX-99.1 to Form 8-K
LINEAGE CELL THERAPEUTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Results of operations · EX-99.1 to Form 8-K
LINEAGE CELL THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Results of operations · EX-99.1 to Form 8-K
CELL THERAPEUTICS ANNOUNCES $14.0 MILLION REGISTERED DIRECT OFFERING
Material agreement · Other events · EX-99.1 to Form 8-K
CELL THERAPEUTICS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Results of operations · EX-99.1 to Form 8-K
CELL THERAPEUTICS REPORTs SECOND QUARTER 2023 FINANCIAL
Results of operations · EX-99.1 to Form 8-K
CELL THERAPEUTICS REPORTs FIRST QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Results of operations · EX-99.1 to Form 8-K
CELL THERAPEUTICS REPORTs FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
CELL THERAPEUTICS REPORTs THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Results of operations · EX-99.1 to Form 8-K
CELL THERAPEUTICS REPORTs SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Results of operations · EX-99.1 to Form 8-K